Trial Profile
An open-label controlled clinical trail of apatinib in the treatment of advanced biliary tract cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 03 Jan 2018 New trial record